The company’s Phase 1 canine osteosarcoma study evaluated the safety and efficacy of ADXS-cHER2 in companion dogs. The study was conducted by Dr. Nicola Mason at the University of Pennsylvania School of Veterinary Medicine. Results of the study show the dogs that received Advaxis immunotherapy are living significantly longer than the dogs whose owners chose not to participate in the study. Dogs with osteosarcoma have a median survival rate of only one year even with standard of care, which consists of amputation of the affected limb and follow-up chemotherapy. The first dog treated in the study, a 13-year-old American bulldog named Sasha, has survived over 600 days.
ADXS-cHER2’s proven ability to prolong the lives of companion dogs is an exciting development for both companion pet treatment and the drug product’s potential for human candidates. Encouraging preliminary data exhibited in the dogs provides strong rationale for clinically developing ADXS-cHER2 as a treatment for women with HER2+ breast cancer.
Advaxis believes this a potentially key value-creating opportunity to provide the company’s immunotherapies for both the veterinary market and for women facing the growing global issue of breast cancer. The company is actively planning a clinical research program in the indication of HER2+ breast cancer in humans.
For more information, visit www.advaxis.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment